Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latex device labeling

This article was originally published in The Gray Sheet

Executive Summary

Combination products currently regulated under human drug or biologic labeling will not be subject to provisions of FDA's final rule requiring label statements for all medical devices that contain or have packaging that contain natural rubber that contacts humans, the agency says in a May 6 Federal Register notice. FDA "intends to initiate a proceeding to propose natural rubber labeling requirements for drugs and biologics, including combination products that are currently regulated under drug or biologic labeling provisions," the agency states in the notice, which is issued as an "interpretation" of its Sept. 30, 1997 final regulation on user labeling for medical devices containing natural rubber ("The Gray Sheet" Oct. 6, 1997, p. 3)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel